Supporting the

Neuroendocrine Cancer Community

NICE approves Avelumab

NICE approves Avelumab

21st APRIL NICE APPROVES AVELUMAB Neuroendocrine Cancer UK is delighted to share with you NICE’s approval of Avelumab as a first line therapy option in metastatic MCC.  Avelumab is now recommended as an option for treating metastatic Merkel cell carcinoma in adults...
NICE launches their 2021-2026 strategy

NICE launches their 2021-2026 strategy

Yesterday, Monday April 19th, NICE launched their 2021-2026 strategy ” a vision for the future”.   According to NICE – Public and patients will see:   – An interactive guideline structure that facilitates links to the underpinning evidence and...